
    
      This study will have 2 cohorts. In Cohort 1, participants who have not received any previous
      therapy for their disease will receive Camrelizumab and Apatinib in combination with
      Oxaliplatin and S-1. In Cohort 2, participants who have received at least one prior therapy
      for their advanced disease will receive Camrelizumab and Apatinib. A Simon two-stage phase II
      design was used for the sample size Calculation.
    
  